Skip to content Skip to footer
Close

Recap with ID-Cap®: Monitoring HIV Medication Adherence in University of Colorado’s QUANTI-TAF Study

  • 449

In collaboration with the University of Colorado, etectRx has made significant strides in advancing medication adherence monitoring through the QUANTI-TAF study (NCT04065347). Recently published in Clinical Infectious Diseases1 and the British Journal of Clinical Pharmacology2, the QUANTI-TAF study focused on antiretroviral therapy (ART) adherence among persons with HIV (PWH) receiving daily oral tenofovir alafenamide/emtricitabine (TAF/FTC)-based ART for at least six months.

Over the course of the study, more than 9,000 ID-Cap® System ingestions contributed to a robust assessment of adherence. 84 participants actively used the ID-Cap System for approximately 4 months each. By combining the digital pill data with drug concentrations, the research team was able to accurately quantify tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots (DBS) at each visit according to adherence level1. Overall, adherence in the study was greater than 90%, and more than 90% of ingestions were detected by the ID-Cap System (as opposed to manually entered)2. The study also found that HIV-1 RNA (plasma viral load) remained suppressed (<200 copies/mL) even in cases of intermittent non-adherence, as measured by the ID-Cap System, reinforcing the potential for digital pill technologies in future research on HIV treatment strategies.

This study highlights the growing promise of digital health innovations by both enhancing medication adherence as well as offering critical insights into the effectiveness of ART regimens in real-world settings. 

Nothing in this content constitutes an endorsement by Ryan Coyle or the University of Colorado.

References

  1. Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, Coppinger C, Barker N, Ellison L, Zheng JH, Al Zuabi S, Alpert PE, Carnes TC, Buffkin DE Jr, Chai PR, Bushman LR, Kiser JJ, MaWhinney S, Brooks KM, Anderson PL, Castillo-Mancilla JR. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024 Nov 22;79(5):1233-1241. doi: 10.1093/cid/ciae212. PMID: 38636950; PMCID: PMC11581703.
  2. Coyle RP, Mainella V, Morrow M, Mann SC, Schwab S, Coppinger C, Barker N, Ellis SL, Carnes TC, Alpert PE, Ellison L, Bushman LR, Brooks KM, MaWhinney S, Castillo-Mancilla JR, Anderson PL. Adherence insights from TAF/FTC-based ART co-encapsulated with an ingestible sensor among virologically suppressed persons with HIV. Coyle RP oral presentation: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, 2024 Sep 18-19; Liverpool, UK. Br J Clin Pharmacol, 90: 10-11. https://doi.org/10.1111/bcp.16291.

Share :